SEC Form 4 · accession 0000874015-26-000245
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joan E Herman
Director
Period of report
Jul 15, 2026
Accepted (ET)
Jul 17, 2026 · 5:12 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 15, 2026 | M | 5,220 | $0.00 | A | 51,306 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF2,F3 | $0.00 | Jul 15, 2026 | M | 5,220 | D | — | — | Common Stock | 5,220 | 2,301 | D |
Explanation of responses
- F1Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
- F2Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
- F3Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.